BiotechTubeBiotechTube
Home/Pipeline/Virtuoso Platform

Virtuoso Platform

Predictive biomarkers for radioligand therapy (Pancreatic NET)

R&D/CollaborationCollaboration with Novartis; data presented at ENETS.

Key Facts

Indication
Predictive biomarkers for radioligand therapy (Pancreatic NET)
Phase
R&D/Collaboration
Status
Collaboration with Novartis; data presented at ENETS.
Company
ClearNote Health, ClearNote Health

About ClearNote Health

ClearNote Health is a commercial-stage diagnostics company leveraging its unique epigenomics platform to detect high-mortality cancers early via a simple blood draw. The company's core technology measures 5-hydroxymethylcytosine (5hmC) modifications in cell-free DNA, providing a sensitive and specific signal of developing cancer. Key achievements include NYSDOH approval and CMS reimbursement for its Avantect tests, selection for the NCI's Vanguard study, and a strategic focus on pancreatic and ovarian cancers. The company is expanding its leadership and commercial footprint to drive clinical adoption.

View full company profile

About ClearNote Health

ClearNote Health is a commercial-stage diagnostics company leveraging its unique epigenomics platform to detect high-mortality cancers early via a simple blood draw. The company's core technology measures 5-hydroxymethylcytosine (5hmC) modifications in cell-free DNA, providing a sensitive and specific signal of developing cancer. Key achievements include NYSDOH approval and CMS reimbursement for its Avantect tests, selection for the NCI's Vanguard study, and a strategic focus on pancreatic and ovarian cancers. The company is expanding its leadership and commercial footprint to drive clinical adoption.

View full company profile

Therapeutic Areas

Oncology